Ab­b­Vie, En­do hit with sub­poe­nas amid Texas AG's at­tempts to lim­it med­ical care for trans youth

Texas of­fi­cials are now in­ves­ti­gat­ing Ab­b­Vie and En­do Phar­ma­ceu­ti­cals as part of the state’s broad­er ef­fort to re­strict gen­der-af­firm­ing care for trans­gen­der chil­dren.

The Texas At­tor­ney Gen­er­al’s of­fice said in a state­ment yes­ter­day that at­tor­ney gen­er­al Ken Pax­ton is­sued a type of ad­min­is­tra­tive sub­poe­na called Civ­il In­ves­tiga­tive De­mands, or CIDs to Ab­b­Vie and En­do, ques­tion­ing whether the phar­mas pro­mot­ed their prod­ucts to chil­dren as pu­ber­ty block­ers for gen­der-af­firm­ing care, which is con­sid­ered an off-la­bel use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER